Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin

Heat shock protein 90 (Hsp90) has been demonstrated to protect oncogenic variants of signalling molecules from degradation and may consequently serve as a therapeutic target for the treatment of oesophageal cancer for which adequate therapy is often lacking. We studied the expression of Hsp90 in tum...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wu, X, Wanders, A, Wardega, P, Tinge, B, Gedda, L, Bergstrom, S, Sooman, L, Gullbo, J, Bergqvist, M, Hesselius, P, Lennartsson, J, Ekman, S
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2009
Gaiak:
Translational Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2634703/
https://ncbi.nlm.nih.gov/pubmed/19142186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604855
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak